GlassScriptPhysician profile
Susan Mildred Harding
NPI 1952396798
$874.21
in general payments reported to CMS, 2019-2025
15 companies · $45.25 in 2025
The $45.25 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.18 · 2020: $35.31 · 2021: $197 · 2022: $305 · 2023: $233 · 2024: $25.70 · 2025: $45.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $303.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $341.78 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $98.75 | 2021-2022 | |
| Pfizer INC. | $96.92 | 2021-2024 | |
| Abbvie INC. | $78.41 | 2021-2025 | |
| Novo Nordisk INC | $48.52 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $34.23 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.14 | 2022-2023 | Xifaxan |
| Kerecis Limited | $27.85 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Janssen Pharmaceuticals, INC | $20.83 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.92 | 2023 | Givlaari |
| Amgen INC. | $19.33 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.92 | 2022 | |
| Lilly USA, LLC | $13.56 | 2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $13.22 | 2022 | |
| Scilex Pharmaceuticals INC. | $11.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.